COHESIVE HEALTHCARE MANAGEMENT & CONSULTING

Mangum Regional Medical Center

TITLE		POLICY
Heparin Standard Dose Protocol – DVT and PE		**DRP-008**
MANUAL	EFFECTIVE DATE	REVIEW DATE
Drug Room	**10-1-2020**	**10-1-2020**
DEPARTMENT	REFERENCE	
Drug Room	**https://www.accessdata.fda.gov**	

SCOPE

This policy applies to all adult patients receiving care and treatment at Mangum Regional Medical Center.

PURPOSE

This protocol applies to adult patients at Mangum Regional Medical Center receiving standard dose heparin intravenous (IV) therapy for Deep Venous Embolism and Pulmonary Embolism.

PROCEDURE

Nursing Orders:

- ☐ Weigh patient STAT. Actual body weight _____ kg
- ☐ Determine Ideal Body Weight _____ kg
- ☐ Determine Adjusted Body weight _____ kg
- ☐ Determine Heparin Dosing Weight (DW): **dose using adjusted body weight if Actual Body Weight/Ideal Body Weight is greater than 1.2. DW _____ kg**

Medications:

☐ Heparin Sodium_____ units IV bolus STAT (_____ mL of 10,000 unit/mL vial).
Bolus dose based on Heparin 80 units/kg x Dosing Weight (**Maximum of 5,000 units)**

☐ Heparin Sodium 25,000 units in D5W 500mL (50 units/mL) at_____ units/hour (_____ mL/hour) begin now.
Heparin 18 units/kg-hour x DW **(Maximum of 1,000 units/hr initially) _____** units/hour

Labs:

- CBC – STAT
- CMP -STAT
- PT/INR - STAT
- PTT - STAT
- PTT every 6 hours after initiation and after every Heparin rate change
- Daily weight while on Heparin Drip
- CBC every other day while on Heparin Drip
- GUAIAC stool as needed

Monitoring Parameters:

- Draw blood for PTT from arm that doesn't have heparin infusion. Do not draw from heparin-flushed lines.

- If there is no other access other than the heparin line, then **stop** the heparin, flush the line, aspirate 10 mL of blood to waste, and then re-flush the line prior to drawing a specimen.

- Do not interrupt heparin infusion unless ordered.

- Contact medical provider if platelet count is less than 150,000 microliter or a 50% drop from baseline; hematoma, bleeding or suspected bleeding occurs.

REFERENCES

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017029s140lbl.pdf

ATTACHMENTS

None.

REVISIONS/UPDATES

Date	Brief Description of Revision/Change